
Ash trees evolving resistance to dieback
The forces of evolution are helping Britain's ash trees to fight back against a deadly fungus that has threatened to decimate the species, a study suggests.
After ash dieback was first recorded in the UK in 2012 experts warned that the disease had the potential to 'change the landscape for ever' by killing up to 90 per cent of Britain's 150 million ash trees, which in 2019 accounted for about 12 per cent of the nation's broadleaf woodland.
However, analysis suggests that natural selection — the evolutionary process first described by Charles Darwin — is already favouring traits that will help young ash survive.
Ash trees were felled in places such as Lower Woods, Gloucestershire, to limit the spread of dieback
ALAMY
Scientists from the Royal Botanic Gardens, Kew, and Queen Mary University of London compared older trees with new saplings. They found thousands of genetic differences that appeared to be allowing younger trees to withstand the fungus more successfully than their predecessors.
Professor Richard Buggs, a senior scientist at Kew and co-author of the study, said the research had raised hopes that ash could fare better than Britain's elms, which were all but wiped out by Dutch elm disease.
'These findings suggest that ash will not go the way of the elm in Britain,' Buggs said. 'Elm trees have struggled to evolve to Dutch elm disease [because of low levels of genetic diversity] but ash are showing a very different dynamic because they produce an abundance of [genetically different] seedlings upon which natural selection can act when they are still young.'
Ash dieback causes leaf loss and stem lesions and often results in trees dying. The research team analysed trees in Marden Park wood in Surrey, a site managed by the Woodland Trust. By studying thousands of variants of different genes, they identified subtle changes between generations.
Charles Darwin's theory of evolution proposes individuals within a species most suited to their environment will survive and pass on those benefits to their offspring
ALAMY
'A tragedy for the trees has been a revelation for scientists, allowing us to show that thousands of genes are contributing to the ash trees' fightback against the fungus,' said Professor Richard Nichols, an evolutionary geneticist at Queen Mary University London.
Even so, the researchers warned that the future of the species in Britain was not guaranteed. 'Natural selection alone may not be enough to produce fully resistant trees. The existing genetic variation in the ash population may be too low and, as the trees become scarcer, the rate of selection could slow,' said Dr Carey Metheringham, an author of the study, which has been published in the journal Science.
'Human intervention, such as selective breeding and the protection of young trees from deer grazing, may be required to accelerate evolutionary change,' Metherington added.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


The Independent
41 minutes ago
- The Independent
Calls to give 65-year-olds automatic Japanese-style health checks
A radical proposal for Japanese-style health "MOTs" for people turning 65 could revolutionise adult social care in England, a new report suggests. The Institute for Public Policy Research (IPPR) argues that this preventative approach would not only enhance the quality of life for older adults but also potentially reduce the number of care home admissions. The think tank's plan aims to curb the "spiralling costs" of adult social care, which burdened local authorities with a £23.3 billion bill in 2023/24. Sir Andrew Dilnot, who spearheaded reform recommendations over a decade ago, has backed the findings, stating that the "yawning and indefensible gap in our collective welfare provision" demands urgent attention. The state of adult social care in England is under review by the Casey Commission, which aims to set out a plan for how to implement a national care service, as promised by Labour in its election manifesto. The first phase of the review is expected to report next year, although recommendations from the initial probe will be implemented in phases over the course of 10 years. Social care leaders have raised concerns over the potential timeline of 2036 for some reforms to be introduced. The second phase of the commission, setting out longer-term reforms, is due to report by 2028. The IPPR has set out its own recommendations, insisting that there should be a 'right to live and age well' as part of any reforms. Among the measures suggested in its latest report is automatic assessment of the care needs of all adults turning 65 as well as those receiving other disability-related benefits. The report stated Government 'should look to the Japanese model of proactive assessments' and while funding will be needed for such a move, 'a more effective state social care system would invest in, not drain, the economy'. The report said Japanese people are automatically assessed for a range of support including home-based help with cooking and dressing to residential respite and some nursing or medical care for long-term conditions when they turn 65 years old. It stated: ' Care is managed by community comprehensive support centres, which employ long-term care specialists, care managers, and social workers. 'This model emphasises preventative care and home-based services, reducing both cost and reliance on institutional care while supporting family caregivers. 'Japan has half the number of people in care homes as the UK, despite a much older population.' The report's other recommendations include investment in exercise groups and community centres to support older people and those with disabilities to stay healthy and active, as well as further training and development for carers, enabling them to give more personalised care. The IPPR also argued there must be a care costs cap, based on Dilnot Commission recommendations, but with additional central Government funding. Proposals for an £86,000 cap on the amount an older or disabled person would have to pay towards their social care support at home or in care homes were scrapped by Labour last year. Sir Andrew, who chaired the 2010 commission into adult social care, said the IPPR paper 'argues powerfully and persuasively that good social care provision can be a wonderful way of enhancing human flourishing'. He added: 'For far, far too long we have had a social care system that fails us all – those who need care, those who provide care, and those who might need care in the future. 'Acting now can transform lives for those with care needs, create a vibrant and exciting care sector, and finally fill this yawning and indefensible gap in our collective welfare provision. Let's do it.' Sir Andrew previously deemed it 'completely unnecessary' to wait three years for the commission's longer-term recommendations and argued it is 'perfectly feasible' for the Government to set out by the end of this year what it is going to do. IPPR research fellow Dr Annie Williamson said: 'A proactive approach to adult social care, including universal MOT-style assessments at 65 and early support, could help people maintain independence for longer while reducing long-term costs. 'A shift to prevention will mean fewer care home admissions, better quality of life for older adults, and more sustainable funding. As the UK grapples with rising demand and strained budgets, this kind of forward-thinking reform offers a way out.' A Department of Health and Social Care spokesperson said: 'Through our 10-Year Health Plan, we will shift healthcare from treatment to prevention to help people live longer, healthier lives. 'This includes diagnosing and treating conditions earlier, predicting and preventing problems before they become serious, and helping people to live healthier lifestyles. 'At the same time, Baroness Casey has begun her work on the Independent Commission into adult social care, which will start a national conversation and provide recommendations for a National Care Service that is fair and affordable for all – and works alongside the NHS.'


The Independent
41 minutes ago
- The Independent
Breakthrough for teen who lost four family members to inherited condition
A teenager who lost four family members to a rare genetic condition has become the first person in Europe to receive a 'life-changing' drug after it was approved for use on the NHS. Mary Catchpole, 19, also has activated PI3-Kinase delta syndrome (APDS), a rare inherited disorder that leaves people with a significantly weakened immune system. Patients with APDS are vulnerable to recurrent infections, often facing a lifetime of antibiotics and invasive medical procedures in an attempt to manage their health. Miss Catchpole's mother's side of the family has been badly affected by APDS – her mother Sarah died aged 43 in 2018, her aunt Helen died aged 12, her uncle Edward when he was 39 and her grandmother Mary when she was 48. Now, thanks to researchers in Cambridge who identified APDS, Miss Catchpole has received a new drug to treat it at Addenbrooke's Hospital in Cambridge. The medicine, called leniolisib (Joenja), is the first ever targeted treatment for APDS and is a simple tablet taken twice a day. Miss Catchpole is a teaching assistant who lives in Great Yarmouth with her father, Jimmy, 64, and brother Joe, 20, who does not have the condition. 'I was diagnosed with APDS aged seven, and it's had a big effect on my life. I had lots of cannulas when I was younger and lots of hospital trips,' she said. 'I had a permanent line in the side of my body when I was younger, which they put medicine in regularly at the hospital. 'I wasn't allowed to do very much physical activity, so I had to sit out a lot in PE at school. 'I used to be called an attention-seeker because obviously it was hidden, so no one really believed me. 'It also stopped me from doing a lot of my dancing, which I've always loved to do. So it has been hard.' Miss Catchpole said taking the new drug is 'life-changing' as it means she can leave behind huge amounts of medication. 'I feel really blessed because it's so simple to do and it doesn't take up very much time, whereas for the medication, it just takes such a long time to do. So it's really a blessing, but it's also obviously bittersweet because my late family members never got the chance to have it.' APDS was identified by Cambridge researchers in 2013, with Miss Catchpole's family playing a key role in its discovery. Her mother and uncle were Addenbrooke's patients and were offered DNA sequencing to see if there was a genetic cause for their immunodeficiency. Researchers identified a change in their genes that increased activity of an enzyme called PI3-Kinase delta, meaning this enzyme is effectively 'switched on' all the time. This prevents immune cells from fighting infection and leads to an abnormal immune function. The new drug works by inhibiting the enzyme, effectively normalising the immune system. Now, Miss Catchpole says she can look to the future with optimism and is excited to lead a normal life. 'I really want to become a dance teacher,' she said. 'I absolutely love my current job as a teaching assistant, but I'd also like to go on some adventures as well. 'I've always felt different, so it will be nice to feel like I belong. 'When I had sleepovers when I was younger and had to take all my medication with me, I didn't feel like a normal child. 'To be able to feel normal going about my day-to-day life is going to be really nice.' Until now, the only treatments for APDS patients were antibiotics for infections, immunoglobulin replacement therapy to prevent infections and organ damage, and a bone marrow or stem cell transplant. Dr Anita Chandra, consultant immunologist at Addenbrooke's and affiliated assistant professor at the University of Cambridge, said going from 'the discovery of a new disease in Cambridge to a treatment being approved and offered on the NHS within the space of 12 years' is 'incredible'. 'This new drug will make a huge difference to people living with APDS.' Professor Sergey Nejentsev, from the University of Cambridge, who led the research that discovered APDS, said: 'As soon as we understood the cause of APDS, we immediately realised that certain drugs could be used to inhibit the enzyme that is activated in these patients. 'Leniolisib does precisely that. I am delighted that we finally have a treatment which will change the lives of APDS patients.' Professor James Palmer, NHS England 's medical director for specialised commissioning, said: 'We're delighted to see Mary become the first patient in Europe to receive this first-ever targeted and approved therapy for a rare condition identified just over a decade ago – in Cambridge, no less. 'This treatment could be life-changing for those affected by this debilitating genetic disorder, and this important step forward is another example of the NHS's commitment to offering access to innovative medicines for those living with rare conditions.' Experts believe the drug will work long-term in patients as long as they keep taking the tablets. Researchers are now looking at the potential for leniolisib to work on other, more common immune conditions. Patients eligible for leniolisib can be referred to Addenbrooke's for specialist review and care. Between 40 to 50 people in England are known to have APDS. The list price for leniolisib is £352,000 per person per year, but the company Pharming has agreed a discount for the NHS. The team that discovered APDS included researchers from the University of Cambridge, Babraham Institute, Medical Research Council (MRC) Laboratory for Molecular Biology, and Addenbrooke's, with funding from Wellcome and the National Institute for Health and Care Research (NIHR).


Daily Mail
an hour ago
- Daily Mail
Mounjaro users panic as new rule is introduced before they can access the next dose
Weight-loss jab users have reacted with fury to a new rule they fear will cut them off from treatment as health bosses clamp down on patients abusing the drugs to get thin rather than taking them for health reasons. Online pharmacies have quietly introduced a requirement for patients to submit full-body photos or videos when they need to renew their prescriptions for the jabs. Your browser does not support iframes. Your browser does not support iframes.